FNY Investment Advisers LLC raised its holdings in MiMedx Group, Inc. (NASDAQ:MDXG – Free Report) by 25.7% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 34,054 shares of the company’s stock after buying an additional 6,956 shares during the period. FNY Investment Advisers LLC’s holdings in MiMedx Group were worth $225,000 at the end of the most recent quarter.
Other institutional investors have also made changes to their positions in the company. Prelude Capital Management LLC acquired a new position in shares of MiMedx Group in the first quarter valued at $42,000. Royce & Associates LP boosted its holdings in shares of MiMedx Group by 21.2% during the first quarter. Royce & Associates LP now owns 842,000 shares of the company’s stock worth $2,871,000 after acquiring an additional 147,000 shares during the period. JPMorgan Chase & Co. grew its position in shares of MiMedx Group by 30.6% in the first quarter. JPMorgan Chase & Co. now owns 90,265 shares of the company’s stock valued at $308,000 after purchasing an additional 21,131 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of MiMedx Group by 4.7% during the first quarter. Geode Capital Management LLC now owns 2,198,537 shares of the company’s stock worth $7,497,000 after purchasing an additional 98,900 shares during the period. Finally, Altium Capital Management LP acquired a new stake in MiMedx Group during the 1st quarter worth approximately $2,551,000. 43.85% of the stock is owned by institutional investors and hedge funds.
MiMedx Group Stock Performance
Shares of MiMedx Group stock traded down $0.16 on Friday, reaching $7.54. 2,358,651 shares of the stock were exchanged, compared to its average volume of 506,319. The firm’s 50 day moving average is $7.49 and its 200-day moving average is $5.76. The firm has a market cap of $875.47 million, a PE ratio of -44.35 and a beta of 1.61. MiMedx Group, Inc. has a one year low of $2.43 and a one year high of $8.60.
Analyst Ratings Changes
MiMedx Group Company Profile
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
- Five stocks we like better than MiMedx Group
- The Dividend Kings With Highest Yield
- 5 Reasons Apple’s New Phone Moves the Needle: 5 That It Won’t
- Stock Dividend Cuts Happen Are You Ready?
- MarketBeat Week in Review – 9/11 – 9/15
- How to Find Cloud Software Company Stocks to Trade and Invest
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.